Shardul Amarchand Mangaldas & Co advises Evonile Pharma Limited on acquisition of ‘Minipress’ and ‘Minipres’ brands from Pfizer

October 22, 2026

Shardul Amarchand Mangaldas & Co (SAM) advised Evonile Pharma Limited, on its acquisition of the ‘Minipress’ and ‘Minipres’ brands in India from Pfizer for an aggregate consideration of approximately ₹1,250 crores. The transaction signed and closed on September 7, 2026.

SAM advised Evonile Pharma Limited on all aspects of the transaction.

The transaction was led by Karun Prakash and Anant Dang (Partners), along with Veena Sivaramakrishnan, J.V. Abhay, Rohan Arora, and Mohit Bhatia (Partners), Devaditya Chakravarti (Counsel), Tanay Khanna (Principal Associate), Leoni Mahanta (Principal Associate), Rahul Shukla (Principal Associate), Yash Kahandole (Principal Associate), Nishal Makharia (Senior Associate), Aagam Jain (Associate), Shivani Pattnaik (Associate), Arushi Tiwari (Associate), Dhruv Bhartia (Associate), Anshika Chadha (Associate) and Anushka Gupta (Associate).